Teva Pharma (TEVA) Tops Q2 EPS by 12c, Offers Guidance

Teva Pharma (NYSE: TEVA) reported Q2 EPS of $0.68, $0.12 better than the analyst estimate of $0.56. Revenue for the quarter came in at $3.8 billion versus the consensus estimate of $3.78 billion.

GUIDANCE:

Teva Pharma sees FY2022 EPS of $2.40-$2.60. Teva Pharma sees FY2022 revenue of $15-15.6 billion.

For earnings history and earnings-related data on Teva Pharma (TEVA) click here.

You May Also Be Interested In

• Concentrix Corporation (CNXC) Misses Q2 EPS by 1c; Guides lower than expectations
• Tesla Q2 deliveries: What to expect from the critical report
• American Outdoor Brands (AOUT) Tops Q4 EPS by 14c